Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis
Stroke · 2026-10 · 57 (10) · 2958-2970
DOI: 10.1161/strokeaha.126.057001 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2026-10. Verfasst von Xiaohui Zi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology (X. Zi, X.X., J.L., X. Zhang, J.J., A.W., Y.W.), Capital Medical University. Hauptthemen laut MEDLINE: Aspirin, Ticagrelor, Ischemic Stroke, Thrombolytic Therapy. Die Arbeit nennt 30 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Whether diffusion‑weighted imaging infarction patterns influence the efficacy and safety of early oral ticagrelor‑aspirin with intravenous thrombolysis in moderate acute ischemic stroke is uncertain. We assessed treatment effects by infarction pattern in this thrombolysis setting. METHODS: This was a subgroup analysis of the TAPIS trial (Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis in Patients With Ischemic Stroke), a 60-center, randomized, double‑blind trial in China. Patients aged 18 to 80 years with noncardioembolic stroke (National Institutes of Health Stroke Scale score 4–10) who received intravenous thrombolysis within 4.5 hours of onset were randomized within 6 hours to ticagrelor‑aspirin or placebo. Diffusion‑weighted imaging patterns were centrally adjudicated as multiple acute infarcts (MAIs; ≥2 lesions) or non‑MAIs (single infarction or diffusion‑weighted imaging–negative). The primary efficacy outcome was modified Rankin Scale score of 0 to 1 at 90 days; safety outcome was symptomatic intracranial hemorrhage. Treatment‑by‑pattern interaction was assessed. RESULTS: Among 1307 patients (94.6% of full analysis set; median age, 65.5 years; 71.2% men; median National Institutes of Health Stroke Scale score, 6.0), 409 (31.3%) had MAIs and 898 (68.7%) non‑MAIs (20.8% diffusion‑weighted imaging–negative, 79.2% single infarction). MAIs were associated with poorer prognosis than non‑MAIs (excellent outcome: 58.9% versus 69.2%; adjusted risk ratio, 0.92 [95% CI, 0.84–1.00]). Ticagrelor‑aspirin was associated with a higher likelihood of excellent outcome versus placebo in MAIs (64.4% versus 53.4%; risk ratio, 1.21 [95% CI, 1.02–1.42]), whereas no significant benefit was observed in non‑MAIs (71.2% versus 67.1%; risk ratio, 1.06 [95% CI, 0.97–1.16]; P interaction =0.18). Early neurological improvement showed significant heterogeneity by infarction pattern ( P interaction =0.02); the treatment‑by‑pattern interaction for the primary outcome was nominally significant after adjusting for rescue tirofiban use ( P =0.04). Symptomatic intracranial hemorrhage occurred in MAIs: 1 of 205 (0.5%) versus 2 of 204 (1.0%); non‑MAIs: 1 of 448 (0.2%) versus 1 of 450 (0.2%). CONCLUSIONS: In thrombolyzed patients with moderate noncardioembolic stroke, MAIs were associated with poorer functional outcomes. Early ticagrelor‑aspirin showed directionally consistent benefits without excess bleeding in patients with MAIs, though the primary interaction was not significant. These hypothesis‑generating findings may inform future trials of diffusion‑weighted imaging infarction pattern as an imaging biomarker to guide antiplatelet therapy in early reperfusion. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06316570.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology (X. Zi, X.X., J.L., X. Zhang, J.J., A.W., Y.W.), Capital Medical University.
- China National Clinical Research Center for Neurological Diseases (X. Zi, X.X., J.L., X. Zhang, J.J., A.W., Y.W.), Capital Medical University.
- Beijing Tiantan Hospital, Department of Clinical Epidemiology and Clinical Trial (X. Zi, X.X., A.W.), Capital Medical University.
- Department of Neurology, Liuyang Jili Hospital, Changsha, China (Y.H.).
- Department of Neurology, Tangshan Gongren Hospital, North China University of Science and Technology (G.C.).
- Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China (Q.W.).
ORCID-Profile: Xiaohui Zi, Guojuan Chen, Qinghua Wang, Xue Xia, Jing Li, Xiaoli Zhang, Jing Jing, Philip M Bath, Guillaume Turc, Anxin Wang, Yilong Wang
Zitieren
APA
Zi, X., He, Y., Chen, G., Wang, Q., Xia, X., Li, J., Zhang, X., Jing, J., Bath, P. M., Turc, G., Wang, A., Wang, Y., & TAPIS Investigators (2026). Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis. Stroke, 57(10), 2958-2970. https://doi.org/10.1161/strokeaha.126.057001
Vancouver
Zi X, He Y, Chen G, Wang Q, Xia X, Li J, et al. Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis. Stroke. 2026;57(10):2958-2970. doi:10.1161/strokeaha.126.057001
BibTeX
@article{Zi2026,
author = {Zi, Xiaohui and He, Yong and Chen, Guojuan and Wang, Qinghua and Xia, Xue and Li, Jing and Zhang, Xiaoli and Jing, Jing and Bath, Philip M and Turc, Guillaume and Wang, Anxin and Wang, Yilong and TAPIS Investigators, TAPIS Investigators},
title = {Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis},
journal = {Stroke},
year = {2026},
volume = {57},
number = {10},
pages = {2958--2970},
doi = {10.1161/strokeaha.126.057001}
}
EUVIMED